Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Aug
03
Today In Oncology
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
NCI Names New CCR Director
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo